Clinic Roundup

• Psivida Corp., of Watertown, Mass., said interim data from a three-year, investigator-sponsored Phase I/II study of its injectable micro-insert in patients with posterior uveitis showed none of the treated eyes had a recurrence of uveitis through the first 12 months of enrollment, and inflammation was reduced in all treated eyes.